RU2721949C2 - Модифицированные цитотоксины и их терапевтическое применение - Google Patents

Модифицированные цитотоксины и их терапевтическое применение Download PDF

Info

Publication number
RU2721949C2
RU2721949C2 RU2018107843A RU2018107843A RU2721949C2 RU 2721949 C2 RU2721949 C2 RU 2721949C2 RU 2018107843 A RU2018107843 A RU 2018107843A RU 2018107843 A RU2018107843 A RU 2018107843A RU 2721949 C2 RU2721949 C2 RU 2721949C2
Authority
RU
Russia
Prior art keywords
fragment
group
compound
protein
compounds
Prior art date
Application number
RU2018107843A
Other languages
English (en)
Russian (ru)
Other versions
RU2018107843A (ru
RU2018107843A3 (OSRAM
Inventor
Кассандра Е. КОЛЛМАНН
Мэттью П. ТОМПСОН
Клэр Л. М. ЛЕГАЙАДЕР
Натан С. ДЖАННЕСКИ
Пол А. БЕРТИН
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Вайбил Холдингз, Инк,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния, Вайбил Холдингз, Инк, filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Publication of RU2018107843A publication Critical patent/RU2018107843A/ru
Publication of RU2018107843A3 publication Critical patent/RU2018107843A3/ru
Application granted granted Critical
Publication of RU2721949C2 publication Critical patent/RU2721949C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
RU2018107843A 2015-09-22 2016-09-21 Модифицированные цитотоксины и их терапевтическое применение RU2721949C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222059P 2015-09-22 2015-09-22
US62/222,059 2015-09-22
PCT/US2016/052829 WO2017053391A1 (en) 2015-09-22 2016-09-21 Modified cytotoxins and their therapeutic use

Publications (3)

Publication Number Publication Date
RU2018107843A RU2018107843A (ru) 2019-10-25
RU2018107843A3 RU2018107843A3 (OSRAM) 2019-11-28
RU2721949C2 true RU2721949C2 (ru) 2020-05-25

Family

ID=58276138

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018107843A RU2721949C2 (ru) 2015-09-22 2016-09-21 Модифицированные цитотоксины и их терапевтическое применение

Country Status (14)

Country Link
US (3) US10023581B2 (OSRAM)
EP (1) EP3353159A4 (OSRAM)
JP (1) JP2018527360A (OSRAM)
KR (1) KR20180045001A (OSRAM)
CN (1) CN108368075A (OSRAM)
AU (1) AU2016326392B2 (OSRAM)
CA (1) CA2998528A1 (OSRAM)
HK (1) HK1254461A1 (OSRAM)
IL (1) IL257932A (OSRAM)
MX (1) MX380314B (OSRAM)
MY (1) MY193776A (OSRAM)
RU (1) RU2721949C2 (OSRAM)
WO (1) WO2017053391A1 (OSRAM)
ZA (1) ZA201801482B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
AU2016326392B2 (en) 2015-09-22 2021-02-11 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
AU2018237139A1 (en) * 2017-03-22 2019-10-17 The Regents Of The University Of California Modified oligonucleotides and therapeutic uses thereof
US20220273607A1 (en) * 2019-07-09 2022-09-01 Northwestern University Methods of using modified cytotoxins to treat cancer
IT202100025172A1 (it) * 2021-09-30 2023-03-30 Indena Spa Processo per la preparazione di derivati tassanici
KR20250057244A (ko) 2023-10-20 2025-04-29 (주)블루엔씨 고정밀 3d 프린팅 기반 금형 제작 방법 및 장치

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2340616C2 (ru) * 2003-10-29 2008-12-10 Сонус Фармасьютикалз, Инк. Токоферол-модифицированные терапевтические лекарственные соединения
WO2011143201A2 (en) * 2010-05-10 2011-11-17 The Regents Of The University Of California Ratiometric combinatorial drug delivery
KR20140017714A (ko) * 2012-07-23 2014-02-12 아주대학교산학협력단 항암제-링커-알부민 결합체, 이의 제조방법 및 상기 결합체를 포함하는 약물 전달용 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
AU6803494A (en) * 1993-06-07 1995-01-03 British Technology Group Limited Anticancer compounds
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
AU735205B2 (en) 1997-05-16 2001-07-05 Commonwealth Scientific And Industrial Research Organisation Vaccine and assay
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
NO319551B1 (no) 2003-07-04 2005-08-29 Thia Medica As Proteinmateriale fra enkeltceller
GB0321613D0 (en) 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
GB0412181D0 (en) * 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
EP1804838A2 (en) * 2004-09-15 2007-07-11 Drug Discovery Laboratory AS Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
TW200731991A (en) * 2005-12-20 2007-09-01 Sonus Pharma Inc Lipophilic di(anticancer drug) compounds, compositions and related methods
WO2009099677A2 (en) 2008-02-08 2009-08-13 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
US20100240883A1 (en) 2009-03-18 2010-09-23 Nian Wu Lipid-drug conjugates for drug delivery
WO2010112942A1 (en) 2009-04-02 2010-10-07 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
EP2521446A2 (en) 2010-01-06 2012-11-14 The University of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
WO2011101261A2 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Purification method
EP2392324A1 (en) * 2010-06-01 2011-12-07 Societe De Coordination De Recherches Therapeutiques Rhenium complexes and their pharmaceutical use
EA024507B1 (ru) 2010-09-28 2016-09-30 Амилин Фармасьютикалс, Ллк Хорошо растворимые лептины
EP3028720A1 (en) 2010-09-28 2016-06-08 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
WO2012048204A2 (en) * 2010-10-08 2012-04-12 Virginia Commonwealth University Prodrugs utilizing a transporter directed uptake mechanism
JP6336902B2 (ja) 2011-06-22 2018-06-06 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド コンジュゲートベースの抗真菌性および抗菌性プロドラッグ
CN104271588B (zh) 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
WO2014078895A1 (en) * 2012-11-21 2014-05-30 The University Of Sydney Omega-3 analogues
US9962452B2 (en) * 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
WO2014201026A2 (en) * 2013-06-10 2014-12-18 Cedars-Sinai Medical Center Antioxidant, anti-inflammatory and anticancer derivatives of triptolide and nanospheres thereof
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EA037519B1 (ru) * 2014-11-17 2021-04-07 Селлектар Байосайенсиз, Инк. Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
CN104478813A (zh) * 2014-12-20 2015-04-01 苏州博源医疗科技有限公司 5-氟尿嘧啶衍生物、5-氟尿嘧啶免疫原及其抗体与5-氟尿嘧啶检测试剂盒
US10286079B2 (en) * 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
AU2016326392B2 (en) * 2015-09-22 2021-02-11 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US20210137874A1 (en) * 2017-03-22 2021-05-13 The Regents Of The University Of California Modified platinum compounds and therapeutic uses thereof
WO2018175595A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified histone deacetylase inhibitors and uses thereof
WO2018175622A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified anthracycline compounds and their therapeutic use
AU2018258345A1 (en) * 2017-04-27 2019-10-17 The Regents Of The University Of California Modified mri contrast agents and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2340616C2 (ru) * 2003-10-29 2008-12-10 Сонус Фармасьютикалз, Инк. Токоферол-модифицированные терапевтические лекарственные соединения
WO2011143201A2 (en) * 2010-05-10 2011-11-17 The Regents Of The University Of California Ratiometric combinatorial drug delivery
KR20140017714A (ko) * 2012-07-23 2014-02-12 아주대학교산학협력단 항암제-링커-알부민 결합체, 이의 제조방법 및 상기 결합체를 포함하는 약물 전달용 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLINE E.N. et al. Paclitaxel-conjugated PAMAN dendrimers adversely affect microtubule structure through two independent modes of action, Biomacromolecules, 2013, v. 14, no. 3, p. 654-664. *
KOUCHAKZADEH H. et al. Efficient delivery of therapeutic agents by using targeted albumin nanoparticles, Advances in Protein Chemistry and Structure Biology, 31.03.2015, v. 98, p. 121-143. *
LI G. et al. Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery, Biomacromolecules, 2011, v. 2, no. 6, p. 2016-2026. *
LI G. et al. Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery, Biomacromolecules, 2011, v. 2, no. 6, p. 2016-2026. CLINE E.N. et al. Paclitaxel-conjugated PAMAN dendrimers adversely affect microtubule structure through two independent modes of action, Biomacromolecules, 2013, v. 14, no. 3, p. 654-664. KOUCHAKZADEH H. et al. Efficient delivery of therapeutic agents by using targeted albumin nanoparticles, Advances in Protein Chemistry and Structure Biology, 31.03.2015, v. 98, p. 121-143. *

Also Published As

Publication number Publication date
US10023581B2 (en) 2018-07-17
RU2018107843A (ru) 2019-10-25
KR20180045001A (ko) 2018-05-03
MY193776A (en) 2022-10-27
AU2016326392B2 (en) 2021-02-11
US10654864B2 (en) 2020-05-19
AU2016326392A1 (en) 2018-03-22
ZA201801482B (en) 2021-07-28
JP2018527360A (ja) 2018-09-20
CA2998528A1 (en) 2017-03-30
US20180222915A1 (en) 2018-08-09
HK1254461A1 (zh) 2019-07-19
US20210047338A1 (en) 2021-02-18
EP3353159A1 (en) 2018-08-01
MX380314B (es) 2025-03-12
WO2017053391A1 (en) 2017-03-30
IL257932A (en) 2018-06-03
MX2018002514A (es) 2018-08-15
EP3353159A4 (en) 2019-03-27
RU2018107843A3 (OSRAM) 2019-11-28
CN108368075A (zh) 2018-08-03
US20170080094A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
RU2721949C2 (ru) Модифицированные цитотоксины и их терапевтическое применение
ES2488841T3 (es) Derivados de alto peso molecular de camptotecinas
JP6262246B2 (ja) ベンダムスチン誘導体およびこれを使用する方法
US20230302144A1 (en) Porphyrin Compounds and Compositions Useful for Treating Cancer
CA3177508A1 (en) Synthetic lipid-like materials for brain delivery
CN105131039B (zh) 一种喜树碱类磷脂化合物、其药物组合物及应用
WO2014118696A2 (en) Pharmacuetical compositions of rapamycin esters and its derivatives
US11071789B2 (en) Pharmaceutical prodrugs and methods of their preparation and use
US20190381179A1 (en) Modified cytotoxins and their therapeutic use
US20210137957A1 (en) Modified anthracycline compounds and their therapeutic use
US20220273607A1 (en) Methods of using modified cytotoxins to treat cancer
WO2018175595A1 (en) Modified histone deacetylase inhibitors and uses thereof
US20200190101A1 (en) Composition Containing Novel Glutamic Acid Derivative And Block Copolymer, And Use Thereof
US20210137874A1 (en) Modified platinum compounds and therapeutic uses thereof
AU2021201809A1 (en) Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
AU2018258345A1 (en) Modified mri contrast agents and uses thereof
HK40008068B (zh) 用於治疗癌症的卟啉化合物和组合物
HK40019846A (en) Modified mri contrast agents and uses thereof
US20190046653A1 (en) Pharmaceutical Preparation Containing Camptothecin-Based Polymeric Derivative